Samuel Riley
Manchester,Greater Manchester
Summary
Scientifically trained healthcare professional with experience in real-world evidence generation, clinical strategy, and multistakeholder engagement across the product lifecycle (pre- and post-HTA). Proven ability to lead advisory boards, Delphi panels, and stakeholder research involving clinicians, payers, and patients, translating complex clinical and economic evidence into actionable insights that influence decision-making. Demonstrated impact on clinical practice, prescribing behaviours, and evidence generation strategies for regulatory and HTA submissions. Particularly experienced in rare and complex disease areas. Seeking to transition into a Medical Science Liaison or Scientific Advisor role, bringing a strong foundation in scientific exchange, KOL engagement, and evidence communication.
Overview
4
4
years of professional experience
1
1
Certification
Work History
Senior Health Technology Assessment (HTA) Analyst
Tolley HTA
Buxton, Derbyshire
11.2025 - Current
- Support pharmaceutical and biotech clients in securing positive HTA outcomes through NICE-aligned evidence generation, with a focus on rare and ultra-rare diseases.
- Lead multistakeholder panels and advisory boards involving clinicians, patients, and payers to inform endpoint selection, evidence strategy, and treatment positioning (e.g. alpha-mannosidosis, Friedreich’s ataxia).
- Apply technical HTA expertise to deliver literature reviews, precedent analyses, and evidence gap assessments, supporting clinical and economic components of HTA submissions.
- Contribute to economic and outcomes research including HRQoL evidence and strategies to address uncertainty in data-sparse settings.
- Actively support business development through conference engagement, client relationship building, and proposal/RfP development.
- Mentored junior analysts, providing guidance and support to foster professional development.
- Analysed complex data sets to identify trends, driving strategic business decisions.
- Developed comprehensive reports summarising analytical findings for stakeholder review.
Associate Consultant
IQVIA, Freelance
Remote
10.2025 - 10.2025
- Delivered short-term freelance project support for an evidence needs assessment focused on driving internal strategic change within a pharmaceutical company’s oncology portfolio, specifically around pricing, reimbursement, and value differentiation in a highly competitive landscape.
- Conducted stakeholder interviews with internal and external stakeholders and performed qualitative analysis to understand how to differentiate “me-too” oncology products across a pan-portfolio.
- Utilised proprietary tools such as HTA Accelerator to synthesise multistakeholder perspectives, competitive intelligence, and payer insights into structured, actionable outputs.
- Identified key evidence gaps and co-authored a strategic report to inform portfolio-level decision-making, pricing strategy, and evidence generation priorities.
Pharmaceutical Pricing Analyst
Access Infinity
Manchester
04.2025 - 07.2025
- Supported global pharmaceutical clients with pricing, reimbursement, and launch strategy through advanced analytics and stakeholder research.
- Leveraged proprietary platforms including NURO to generate bespoke, real-time insights based on live market data, informing pricing decisions, launch sequencing, and evidence generation strategies.
- Designed and delivered stakeholder research involving clinicians, KOLs, and former HTA assessors across global markets (UK, EU, US, Japan), integrating findings with quantitative outputs from proprietary tools.
- Applied insights to support gap analyses, competitive positioning, and payer strategy, translating complex data into actionable recommendations for client decision-making.
- Designed and implemented research activities involving healthcare professionals, key opinion leaders, and former HTA assessors, often using double-blinded methodologies.
- Contributed to research across the product lifecycle, including early-phase gap analyses, indication sequencing, competitive intelligence, and post-launch activities such as payer tracking and advisory boards.
- Synthesised research outputs into strategic recommendations that informed launch planning, evidence development priorities, and communication strategies tailored to specific payer environments.
Senior Pharmaceutical Analyst
Adelphi Values PROVE
Macclesfield
12.2024 - 04.2025
- Acted as the primary contributor across complex, multi-stakeholder research projects, with a strong focus on designing and delivering advisory boards, multistakeholder panels, and Delphi studies involving clinicians and payers.
- Led the design and execution of Delphi panels and advisory boards to generate consensus on clinically and payer-relevant topics, including barriers to adoption of disease-specific patient-reported outcomes and physician decision-making in treatment-resistant depression (esketamine).
- Engaged directly with healthcare professionals, key opinion leaders (KOLs), and payer stakeholders to generate insights that informed evidence generation strategies, clinical positioning, and value communication.
- Delivered a broad range of primary research methodologies, including structured expert elicitation (SEE), discrete choice experiments (DCEs), and qualitative interviews, leveraging patient and clinician insights and translating these into quantitative, decision-relevant outputs to support HTA and payer decision-making.
- Contributed to secondary research and evidence generation, including systematic and targeted literature reviews (SLRs/TLRs), HTA evidence synthesis, and development of global value dossiers and submission materials.
- Supported publication strategy and dissemination, co-authoring peer-reviewed manuscripts and conference abstracts, ensuring evidence generation activities translated into scientific outputs.
- Managed the full research lifecycle, from study design and stakeholder recruitment through to analysis and final presentation, delivering high-quality reports and presentations tailored to clinical, payer, and policy audiences.
- Built and maintained strong client relationships, acting as a key point of contact while managing timelines, budgets, and external vendors. Contributed to mentoring and internal capability building through training and knowledge sharing initiatives.
Pharmaceutical Analyst
Adelphi Values PROVE
Macclesfield
09.2022 - 12.2024
- Supported the design and delivery of numerous real-world evidence studies, non-interventional observational clinical studies, and health technology assessments.
- Led the development of study protocols for both primary and secondary research, ensuring alignment with ethical standards, regulatory guidance, and good clinical practice (GCP).
- Managed external recruitment of patients, healthcare professionals, pharmaceutical payers, and policy stakeholders across multiple markets.
- Conducted high-quality literature reviews, health technology assessment (HTA) extractions and evidence synthesis.
- Co-authored peer-reviewed publications and contributed to abstracts and posters presented at international congresses.
Education
GCSEs -
Wellington Road Secondary School
Altrincham 01-2018
BSc - Biological Sciences With International Placement Year
University of Birmingham
01-2022
International placement year - Molecular Biology
University of Zürich
Switzerland01-2022
A-Levels -
Wellington Road Sixth Form
Altrincham 01-2019
Skills
- Real-world evidence (RWE) generation and clinical research within ICH-GCP and ethical frameworks
- Health Technology Assessment (HTA) processes including NICE and MHRA frameworks
- Primary and secondary research: advisory boards, Delphi panels, DCEs, SEE, qualitative & quantitative studies
- Evidence synthesis: systematic and targeted literature reviews, HTA evidence extraction, and reporting
- Market access and payer strategy: pricing, reimbursement, competitive intelligence, and value communication
- Stakeholder engagement: KOLs, clinicians, payers, and multidisciplinary teams across global settings
- Scientific communication: presenting complex clinical and economic data to technical and non-technical audiences
- Publication and dissemination: manuscripts, conference abstracts, and scientific outputs
- Data analysis and tools: Excel, R (basic), data visualisation, and exploratory analysis
- Project management: end-to-end delivery of research projects, timelines, budgets, and client coordination
- Scientific foundation: molecular and cellular biology techniques and pre-clinical research methods
- Cross-functional collaboration
- Client relationship management
- Literature synthesis
- Proposal development
- Systematic reviews
- Stakeholder engagement
- Evidence generation
- Strategic planning
Core competencies
- Scientific exchange and stakeholder engagement
- Advisory boards and Delphi panel design and delivery
- Clinical and real-world evidence interpretation
- KOL, payer, and patient engagement
- Medical strategy across the product lifecycle
- Rare disease and complex evidence landscapes
- HTA, NICE, and payer decision-making
- Cross-functional collaboration
Certification
UK Driving License
Custom Section
Strong understanding of ICH-GCP, clinical trial lifecycle, research governance, and ethical frameworks., Familiar with UK healthcare reforms, NICE, MHRA, and HTA processes., Experienced in multi-stakeholder qualitative & quantitative studies., Skilled in literature reviews, HTA extraction, evidence synthesis., Led research workstreams, managed recruitment and vendor relationships., Proficient in Microsoft Office, data visualization, and reporting., Skilled at presenting complex clinical data to diverse audiences., Experienced in global market engagement., Proactive, self-motivated, confidentiality-aware., Willing to travel and adapt to multidisciplinary team needs.
Websites, Portfolios and Profiles
https://www.linkedin.com/in/sam-riley-560a52188/
Publications
- EPH171 Clinical, Economic, and Patient-Reported Impact of Obesity in the Asia-Pacific Region: A Systematic Review, Artime, E., Franceschini, M., Riley, S., Mount, J.E., Tahbaz, A., Flannery, C. and Newson, R.S., Value in Health, 2023, 26, 12, S235
- Clinical outcome measures and biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A literature review, Rajabally, Y.A., Boggia, G.M., Gary, C., Noel, W., Riley, D., Riley S., Nobile-Orazio, E., European Academy of Neurology, ePresentation
- A, Young., A Reif., A, Fagiolini., Y, Godinov., R, Perry. Key considerations on treatment duration: expert consensus recommendations using the Delphi method on esketamine nasal spray for treatment-resistant depression. European College of Neuropsychopharmacology [In acknowledgements]
- Glass, J., Artime, E., Longuet, C., Khare S., Riley, S., Kewley, R., Kuk J.L., Patton, I., Lau, D.C.W, 2024. Humanistic and economic burden, guidelines and access policies of obesity treatment in Canada: A systematic review. Canadian Medical Association Journal.
References
- Daisy Bridge, Project manager, daisy.bridge@adelphivalues.com
- Leanne Taylor-Smith, Lab Project Supervisor, l.m.taylorsmith@bham.ac.uk
Timeline
Senior Health Technology Assessment (HTA) Analyst
Tolley HTA
11.2025 - Current
Associate Consultant
IQVIA, Freelance
10.2025 - 10.2025
Pharmaceutical Pricing Analyst
Access Infinity
04.2025 - 07.2025
Senior Pharmaceutical Analyst
Adelphi Values PROVE
12.2024 - 04.2025
Pharmaceutical Analyst
Adelphi Values PROVE
09.2022 - 12.2024
GCSEs -
Wellington Road Secondary School
BSc - Biological Sciences With International Placement Year
University of Birmingham
International placement year - Molecular Biology
University of Zürich
A-Levels -
Wellington Road Sixth Form